Esperion Therapeutics (ESPR) Liabilities and Shareholders Equity (2012 - 2026)

Esperion Therapeutics' Liabilities and Shareholders Equity history runs 15 years deep, the most recent figure standing at $462.5 million for Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 42.74% year-over-year to $462.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 billion (up 22.88% YoY) and the FY2025 annual result came in at $465.9 million, up 35.5% from the prior year.
• Liabilities and Shareholders Equity was $462.5 million for Q1 2026 at Esperion Therapeutics, down from $465.9 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $465.9 million in Q4 2025 and bottomed at $205.8 million in Q4 2023.
• A 5-year average of $321.6 million and a median of $324.0 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity plunged 35.02% — and 2024, when it soared 67.07%.
• Esperion Therapeutics' Liabilities and Shareholders Equity stood at $247.9 million in 2022, then fell by 17.0% to $205.8 million in 2023, then soared by 67.07% to $343.8 million in 2024, then jumped by 35.5% to $465.9 million in 2025, then fell by 0.72% to $462.5 million in 2026.
• Business Quant data shows ESPR's Liabilities and Shareholders Equity at $462.5 million in Q1 2026, $465.9 million in Q4 2025, and $364.0 million in Q3 2025.